Combining ligand-based pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening for the discovery of new potent hormone sensitive lipase inhibitors

Journal of Medicinal Chemistry

Volumn 51, Issue 20, 2008, Pages 6478-6494

  Taha, Mutasem O ^a   Dahabiyeh, Lina A ^a   Bustanji, Yasser ^a   Zalloum, Hiba ^a   Saleh, Suhair ^b  

^a UNIVERSITY OF JORDAN   (Jordan)

^b APPLIED SCIENCE PRIVATE UNIVERSITY   (Jordan)

Author keywords

[No Author keywords available]

Indexed keywords

AGRICULTURAL CHEMICAL; BENZYL BENZOATE; BIFENOX; CAPSAICIN; CHLORFENSON; DIBENZOYLMETHANE; ENZYME INHIBITOR; ETHIOFENCARB; FENPROPATHRIN; FENVALERATE; HERBICIDE; HORMONE SENSITIVE LIPASE; HORMONE SENSITIVE LIPASE INHIBITOR; NAPROXEN; OXYBENZONE; SILAFLUOFEN; UNCLASSIFIED DRUG;

ALGORITHM; ARTICLE; CALCULATION; COMPUTER MODEL; COMPUTER PROGRAM; COVALENT BOND; CRYSTAL STRUCTURE; DATA BASE; DIABETES MELLITUS; DRUG BINDING SITE; DRUG IDENTIFICATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG STRUCTURE; ENZYME ASSAY; IC 50; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; NONHUMAN; OBESITY; PHARMACOPHORE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RAT; STRUCTURE ANALYSIS; TECHNIQUE;

ANIMALS; COMPUTATIONAL BIOLOGY; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; LIGANDS; MALE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RATS; RATS, WISTAR; STEROL ESTERASE;

EID: 54549084551     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800718k     Document Type: Article

References (44)

1. Bailey, C. J. Potential new treatments for type 2 diabetes. TiPS 2000, 21, 259-265.
2. Miles, J. M.; Nelson, R. H. Contribution of triglyceride-rich lipoproteins to plasma free fatty acids. Horm. Metab. Res. 2007, 39, 726-729.
3. Frayn, K. N. Adipose tissue as a buffer for daily lipid flux. Diabetologia 2002, 45, 1201-1210.
4. Kim, J. K.; Fillmore, J. J.; Chen, Y.; Yu, C.; Moore, I. K.; Pypaert, M.; Lutz, E. P.; Kako, Y.; Velez-Carrasco, W.; Goldberg, I. J.; Breslow, J.; Schulman, G. I. Tissue-specific over expression of lipoprotein lipase causes tissue-specific insulin resistance. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 7522-7527.
5. Pfeiffer, A. F. Adipose tissue and diabetes therapy: do we hit the target? Horm. Metab. Res. 2007, 39, 734-738.
6. Kraemer, F. B.; Shen, W. Hormone-Sensitive Lipase Knockouts. Nutr. Metab. 2006, 12, 1-7.
7. Lowe, D. B.; Magnuson, S.; Oi, N.; Campbell, A.; Cook, J.; Hong, Z.; Wang, M.; Rodriguez, M.; Achebe, F.; Kluender, H.; Wong, W. C.; Bullock, W. H.; Salhanick, A.I.; Witman, J. T.; Bowling, M. E.; Keiperb, C.; Clairmont, K. B. In vitro SAR of (5-(2H)-isoxazolonyl) ureas, potent inhibitors of hormone-sensitive lipase. Bioorg. Med. Chem. Lett. 2004, 14, 3155-3159.
8. Jianping, Y. Role of Insulin in the Pathogenesis of Free Fatty Acid-Induced Insulin Resistance in Skeletal Muscle. Endocr. Metab. Immune Disord.: Drug Targets 2007, 7, 65-74.
9. Holm, C. Molecular mechanisms regulating hormone-sensitive lipase and lipolysis. Biochem. Soc. Trans. 2003, 31, 1120-1124.
10. Ebdrup, S.; Sorensen, L. G.; Olsen, O. H.; Jacobsen, P. Synthesis and Structure-Activity Relationship for a Novel Class of Potent and Selective Carbamoyl-Triazole Based Inhibitors of Hormone Sensitive Lipase. J. Med. Chem. 2004, 47, 400-410.
11. Ebdrup, S.; Hoffmann, H.; Refsgaard, F.; Fledelius, C.; Jacobsen, P. Synthesis and Structure-Activity Relationship for a Novel Class of Potent and Selective Carbamate-Based Inhibitors of Hormone Selective Lipase with Acute in Vivo Antilipolytic Effects. J. Med. Chem. 2007, 50, 5449-5456.
12. Slee, D. H.; Bhat, A. S.; Nguyen, T. N.; Kish, M.; Lundeen, K.; Newman, M. J.; McConnell, S. J. Pyrrolopyrazinedione-Based Inhibitors of Human Hormone-Sensitive Lipase. J. Med. Chem. 2003, 46, 1120-1122.
13. Shoenafinger, K.; Petry, S.; Mueller, G.; Barringhous, K.-H. PCT Appl. WO 0166533, 2001.
14. Petry, S.; Schoenafinger, K.; Mueller, G.; Barringhous, K.-H. PCT Appl. WO 0117981, 2001.
15. De Jong, J. C.; Sorensen, L. G.; Tornqvistc, H.; Jacobsen, P. Carbazates as potent inhibitors of hormone-sensitive lipase. Bioorg. Med. Chem. Lett. 2004, 14, 1741-1744.
16. Ebdrup, S.; Jacobsen, P.; Dhanda Farrington, A.; Vedsø, P. Structure-activity relationship for aryl and heteroaryl boronic acid inhibitors of hormone-sensitive lipase. Bioorg. Med. Chem. 2005, 13, 2305-2312.
17. CATALYST 4.11 Users' Manual; Accelrys Software Inc.: San Diego, CA, 2005.
18. Sprague, P. W.; Hoffmann, R. In Computer Assisted Lead Finding and Optimization. Current Tools for Medicinal Chemistry; Van de Waterbeemd, H., Testa, B., Folkers, G., Eds.; VHCA: Basel, Switzerland, 1997; pp 230-240.
19. Barnum, D.; Greene, J.; Smellie, A.; Sprague, P. Identification of common functional configurations among molecules. J. Chem. Inf. Comput. Sci. 1996, 36, 563-571.
20. Smellie, A.; Teig, S.; Towbin, P. Polling: Promoting Conformational Variation. J. Comput. Chem. 1995, 16, 171-187.
21. Li, H.; Sutter, J.; Hoffmann, R. In Pharmacophore Perception, Development, and Use in Drug Design; Güner, O. F., Ed.; International University Line: La Jolla, CA, 2000; pp 173-189.
22. Sutter, J.; Güner, O.; Hoffmann, R.; Li, H.; Waldman, M. In Pharmacophore Perception, Development, and Use in Drug Design; Güner, O. F., Ed.; International University Line: La Jolla, CA, 2000; pp 501-511.
23. Kurogi, Y.; Guner, O. F. Pharmacophore modeling and three dimensional database searching for drug design using catalyst. Curr. Med. Chem. 2001, 8, 1035-1055.
24. Bersuker, I. B.; Bahçeci, S.; Boggs, J. E. In Pharmacophore Perception, Development, and Use in Drug Design; Güner O. F., Ed.; International University Line: La Jolla, CA, 2000; pp 457-473.
25. Poptodorov, K.; Luu, T.; Langer, T.; Hoffmann, R. In Methods and Principles in Medicinal Chemistry. Pharmacophores and Pharmacophores Searches; Hoffmann, R. D., Ed.; Wiley-VCH: Weinheim, Germany, 2006; Vol. 2, pp 17-47.
26. Singh, J.; Chuaqui, C. E.; Boriack-Sjodin, P. A.; Lee, W. C.; Pontz, T.; Corbley, M. J.; Cheung, H. K.; Arduini, R. M.; Mead, J. N.; Newman, M. N.; Papadatos, J. L.; Bowes, S.; Josiah, S.; Ling, L. E. Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFbeta receptor kinase (TbetaRI). Bioorg. Med. Chem. Lett. 2003, 13, 4355-4359.
27. Taha, M. O.; Qandil, A. M.; Zaki, D. D.; AlDamen, M. A. Ligand-based assessment of factor Xa binding site flexibility via elaborate pharmacophore exploration and genetic algorithm-based QSAR modeling. Eur. J. Med. Chem. 2005, 40, 701-727.
28. Taha, M. O.; Bustanji, Y.; Al-Ghussein, M. A. S.; Mohammad, M.; Zalloum, H.; Al-Masri, I. M.; Atallah, N. Pharmacophore Modeling, Quantitative Structure-Activity Relationship Analysis and In Silico Screening Reveal Potent Glycogen Synthase Kinase-3β Inhibitory Activities for Cimetidine, Hydroxychloroquine and Gemifloxacin. J. Med. Chem. 2008, 51, 2062-2077.
29. Taha, M. O.; Atallah, N.; Al-Bakri, A. G.; Paradis-Bleau, C.; Zalloum, H.; Younis, K.; Levesque, R. C. Discovery of New MurF Inhibitors via Pharmacophore Modeling and QSAR Analysis followed by in silico screening. Bioorg. Med. Chem. 2008, 16, 1218-1235.
30. Taha, M. O.; Al-Bakri, A. G.; Zalloum, W. A. Discovery of potent inhibitors of pseudomonal quorum sensing via pharmacophore modeling and in silico screening. Bioorg. Med. Chem. Lett. 2006, 16, 5902-5906.
31. Taha, M. O.; Bustanji, Y.; Al-Bakri, A. G.; Yousef, M.; Zalloum, W. A.; Al-Masri, I. M.; Atallah, N. Discovery of new potent human protein tyrosine phosphatase inhibitors via pharmacophore and QSAR analysisfollowed by in silico screening. J. Mol. Graphics Modell. 2007, 25, 870-884.
32. Sheridan, R. P.; Kearsley, S. K. Why do we need so many chemical similarity search methods? Drug Discovery Today 2002, 7, 903-911.
33. Fischer, R. The Principle of Experimentation Illustrated by a PsychoPhysical Experiment, 8th ed.; Hafner Publishing: New York, 1966; Chapter II.
34. CERIUS2, QSAR Users' Manual, version 4.10; Accelrys Inc.: San Diego, CA, 2005; pp 43-88, 221-235.
35. Ramsey, L. F.; Schafer, W. D. The Statistical Sleuth, 1st ed.; Wadsworth Publishing Company: Belmont, CA, 1997.
36. Clement, O. O.; Mehl, A. T. Pharmacophore Perception, Development, and Use in Drug Design. In IUL Biotechnology Series; Guner, O. F., Ed.; International University Line: La Jolla, CA, 2000; pp 71-84.
37. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 2001, 46, 3-26.
38. Veber, D. F.; Johnson, S. R.; Cheng, H. Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 2002, 45, 2615-2623.
39. European Food Safety Authority. Conclusion regarding the peer review of the pesticide risk assessment of the active substance, bifenox. Sci. Rep. 2007, 119, 1-84.
40. Langin, D.; Laurell, H.; Holst, L. S.; Beifrage, P.; Holm, C. Gene Organization and primary structure of human hormonesensitive lipase: possible significance of a sequence homology with a lipase of Moraxella TA144, an antarctic bacterium. Biochem. J. 1993, 90, 4897-4901.
41. Krovat, E. M.; Langer, T. Non-Peptide Angiotensin II Receptor Antagonists: Chemical Feature Based Pharmacophore Identification. J. Med. Chem. 2003, 46, 716-726.
42. Rodbell, M. Metabolism of Isolated Fat Cells. J. Biol. Chem. 1964, 293, 375-380.
43. Morimoto, C.; Sumiyoshi, M.; Kameda, K.; Tsujita, T.; Okuda, H. Relationship between Hormone-Sensitive Lipolysis and Lipase Activity in Rat Fat Cells. J. Biochem. 1999, 125, 976-981.
44. Petry, S.; Baringhaus, K. H.; Schoenafinger, K.; Jung, C.; Kleine, H.; Müller, G. HTS of Hormone sensitive Lipase and Subsequent Computer-assisted Compound Optimization. In Lipases and Phospholipases in Drug Development; Mueller, G., Petry, S., Eds.; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, 2004; pp 121-137.